title: Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China.
abstract: BACKGROUND
  To report the clinical outcomes in Chinese patients with primary open-angle glaucoma and ocular hypertension treated with bimatoprost 0.03% therapy.
  
  
  METHODS
  Two hundred sixty-three Chinese patients with primary open-angle glaucoma and ocular hypertension who needed initial or additional intraocular pressure (IOP) lowering were recruited in this prospective, open-label, multicenter clinical study and were treated with bimatoprost 0.03%. Patients received bimatoprost 0.03% as initial, replacement or adjunctive IOP-lowering therapy, and follow-up visits were performed at week 1, and month 1 and 3 of the bimatoprost treatment. The efficacy outcome measure was the post-treatment IOP level. The safety outcome measures included the rate of medication-related symptoms, physical signs, reported adverse events, and the level of conjunctival hyperemia.
  
  
  RESULTS
  Among 240 patients who could be categorized by pre-existing therapies and the bimatoprost therapy regimen in the study, IOP values observed in all medication conditions showed significant IOP reduction at all study visits compared with baseline. At 3 months, 8.0 ± 3.7 mmHg (32.0%) reduction in IOP was observed in treatment-naive patients after bimatoprost monotherapy; in the patients previously on various therapy regimens, 1.9 ± 2.8 mmHg (9.5%) to 6.4 ± 6.1 mmHg (24.8%) additional IOP lowering was achieved after switching to bimatoprost monotherapy or bimatoprost combination therapy. The most common adverse event was conjunctival hyperemia, mainly of trace and mild intensity.
  
  
  CONCLUSIONS
  Our results show that bimatoprost 0.03% was effective in lowering IOP with favorable safety in Chinese primary open-angle glaucoma and ocular hypertension patients.
authors.forename: Kaidi
authors.initials: K
authors.lastname: Wang
authors.forename: Li
authors.initials: L
authors.lastname: Xu
authors.forename: Zhilan
authors.initials: Z
authors.lastname: Yuan
authors.forename: Ke
authors.initials: K
authors.lastname: Yao
authors.forename: Junmei
authors.initials: J
authors.lastname: Zhao
authors.forename: Liang
authors.initials: L
authors.lastname: Xu
authors.forename: Aiwu
authors.initials: A
authors.lastname: Fang
authors.forename: Mingzhi
authors.initials: M
authors.lastname: Zhang
authors.forename: Lingling
authors.initials: L
authors.lastname: Wu
authors.forename: Jian
authors.initials: J
authors.lastname: Ji
authors.forename: Jiamin
authors.initials: J
authors.lastname: Hou
authors.forename: Qing
authors.initials: Q
authors.lastname: Liu
authors.affiliation: Eye & ENT Hospital, Shanghai Medical College, Fudan University, Fenyang Road 83, Shanghai, Xuhui District 200031, China. xhsun.sh@hotmail.com.
authors.forename: Xinghuai
authors.initials: X
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D000577:Amides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000069580:Bimatoprost; D002681:China; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003229:Conjunctival Diseases / Q000139:chemically induced; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D006940:Hyperemia / Q000139:chemically induced; D007429:Intraocular Pressure / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies
chemical_list: D000577:Amides; D000959:Antihypertensive Agents; D003008:Cloprostenol; D000069580:Bimatoprost